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A gain-of-function R620W polymorphism in the PTPN22 gene, encoding the lymphoid tyrosine phosphatase
LYP, has recently emerged as an important risk factor for human autoimmunity. Here we report that another
missense substitution (R263Q) within the catalytic domain of LYP leads to reduced phosphatase activity.
High-resolution structural analysis revealed the molecular basis for this loss of function. Furthermore, the
Q263 variant conferred protection against human systemic lupus erythematosus, reinforcing the proposal
that inhibition of LYP activity could be beneficial in human autoimmunity.
INTRODUCTION
PTPN22 encodes the protein tyrosine phosphatase (PTP) LYP,
which is a critical gatekeeper of T-cell receptor (TCR) signaling.
In T-cells, LYP (lymphoid tyrosine phosphatase) potently inhi-
bits signaling through dephosphorylation of several substrates,
including the Src-family kinases Lck and Fyn, as well as
ZAP-70 and TCRzeta (1,2). Recently, PTPN22 has emerged as
an important genetic risk factor for human autoimmunity.
Specifically, an R620W missense single nucleotide polymorph-
ism (SNP) (rs2476601) in exon 14 of PTPN22 is associated with
type 1 diabetes (T1D) (3), rheumatoid arthritis (4), systemic
lupus erythematosus (SLE) (5), and other autoimmune diseases
(reviewed in 6). The R620W substitution occurs within a
protein–protein interaction domain and results in a gain of func-
tion that inhibits TCR signaling (7,8). Reduced TCR signaling
has recently been recognized as a risk factor for autoimmunity
and affects disease predisposition by multiple mechanisms,
including altered thymic selection, reduced T-helper activity,
and decreased number/function of regulatory T-cells (9).
In this study, we sought to determine whether another
amino acid substitution, R263Q (G788A, rs33996649) within
the catalytic domain of the enzyme, is functional with
respect to TCR signaling and phosphatase activity.
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RESULTS
We first compared the effect of the R263Q variant on
TCR-induced phosphorylation of intracellular proteins at the
single cell level by phospho-specific flow cytometry (Fig. 1A–
C). Compared with the wild-type R263 allele (continuous
graphs), the Q263 allele (dotted graphs) was less efficient in
reducing the phosphorylation of SLP-76, an early mediator of
TCR signaling downstream of LYP (Fig. 1C). The Q263
variant was also less efficient in inhibiting the TCR-induced acti-
vation of extracellular-signal regulated kinase (ERK) (Fig. 1D)
and the TCR-induced activation of an NFAT/AP1 luciferase
reporter (Fig. 1E). Taken together, these data suggest that
Q263 is a loss-of-function variant of LYP.
Because the R263Q polymorphism is located within the cata-
lytic domain of the phosphatase, we hypothesized that the appar-
ent loss of function is due to reduced phosphatase activity.
Consistent with this notion, the phosphatase activity of the
Q263 variant was lower than that of R263 (Fig. 2A). To assess
this, we generated constructs encoding the catalytic domain of
LYP, purified the two allelic variants (Cat-R263 and Cat-Q263,
see Fig. 2B), and assayed their activity on a 14-amino acid
peptide derived from the Y394 phosphorylation site of Lck, a
physiological substrate of LYP. The Cat-Q263 variant showed
lower specific activity than Cat-R263 on the physiological
peptide (Fig. 2C). Cat-Q263 also showed lower activity than
Cat-R263 when two non-specific PTP substrates were used
(Fig. 2D and E). Based on these data, we conclude that the
R263Q substitution decreases LYP phosphatase activity.
To determine the structural basis underlying this loss-of-
function phenotype, we solved the crystal structures of the
catalytic domain of the Q263 LYP mutant and the wild-type
allele. Based on our new derivation (Fig. 3A; Table 1) as
well as that recently reported by Yu et al. (10), the overall
structure of Cat-Q263 is similar to that of the wild-type
allele. However, the a20 helix of Cat-Q263 is significantly dis-
placed (Fig. 3A) as a result of a loss of the stabilizing contact
that normally occurs between R263 of a5 and Q34 of a20
(Fig. 3B). Thus, substitution of Q at position 263 disrupts
the conformation of the loop between the a1 and a20
helices, which has been shown to be LYP-specific and to par-
ticipate in substrate binding (10). This results in an extended
a20 helix that exposes the critical S35 residue toward the
outer surface of the enzyme. In addition, the flexible Trp-
P20-Glu (WPD) loop that provides the hydrophobic pocket,
which buries the phosphotyrosine and stabilizes the
phosphoryl-cysteine intermediate, is in an open conformation
with Cat-Q263, whereas it is half-closed in wild-type LYP
(Fig. 3C). Furthermore, a comparison of surface electrostatics
between Cat-R263 and Cat-Q263 (Fig. 3D and E) demon-
strates that, despite preserving the electropositive nature of
the substrate-binding cleft with a hydrophobic boundary, the
conformation and depth of the cleft in the Cat-Q263 mutant
is different from that of Cat-R263, which could potentially
disrupt catalysis. These data provide a plausible molecular
mechanism through which the Q263 variant leads to a loss of
function. Recently, Yu et al. (10) identified a specific small mol-
ecule inhibitor of LYP called IC-11. Co-crystallization analysis
showed that IC-11 extensively interacts with the same a1–a20
loop, which is affected by the R263Q polymorphism (10).
Therefore, we also assessed the inhibitory action of IC-11 on
Cat-R263 and Cat-Q263, and found that IC-11 is significantly
less potent on the Q263 variant of the phosphatase (Fig. 4),
which lends further support to our model of the structural
effect of the R263Q polymorphism.
Given that the R620W variant with a gain-of-function effect
predisposes individuals to autoimmunity, we reasoned that the
loss-of-function nature of the R263Q polymorphism may have
a protective effect against autoimmunity. We therefore exam-
ined the impact of the R263Q variant on patients with SLE, a
systemic autoimmune disease. We genotyped a cohort of 881
SLE patients and 1133 healthy Controls of Caucasian ancestry
(Spain) and observed a significant protective effect of the
Q263 allele which was present at a higher frequency in Con-
trols compared with Cases [odds ratios (OR) 0.58, 95% confi-
dence interval (CI) 0.38–0.86, P ¼ 0.006] (Table 2). To
confirm this association, we genotyped the R263Q genetic
variant in three independent replication populations (Italian,
Argentinean and Caucasian North American). Genotype fre-
quencies were in Hardy–Weinberg equilibrium in patients
and Controls in all four populations. The Q263 protective
effect was observed in all three cohorts, although the
P-values did not reach significance likely due to their
smaller sample sizes. The Breslow–Day test showed hom-
ogeneity of the four populations allowing us to perform a com-
bined analysis with a total of 2093 SLE patients and 2348
Controls, which confirmed the protective effect of the Q263
loss-of-function allele (pooled OR 0.63, 95% CI 0.47–0.84,
P ¼ 0.0017) (Table 2). It should be noted that these results
are obtained from Caucasians and we cannot exclude the
possibility that underlying genetic substructure within
European-derived populations may affect the association of
the R263Q with SLE. This may be particularly relevant in
the US cohort, which is a combination of Cases and Controls
from two recruitment sites. Previous studies demonstrated that
the R620W and the R263Q non-synonymous polymorphisms
are in independent PTPN22 haplotypes (11,12). Therefore, it
could be suggested that these genetic variants exert indepen-
dent effects on genetic susceptibility to SLE. To test this
hypothesis, we first examined linkage disequilibrium (LD)
between the R620W and R263Q polymorphisms and observed
that these variants were completely independent (r2 ¼ 0).
Although the low frequency of the R263Q variant precluded
a complete test of interaction between the two SNPs, we per-
formed an analysis with the R263Q SNP by conditioning on
R620W and observed that the association of the R263Q poly-
morphism with SLE is independent of the R620W SNP (P ¼
0.003 for the association of R263Q polymorphism conditioned
on R620W).
Because the R620W SNP, which predisposes to a variety of
autoimmune-related disorders, shows extreme frequency vari-
ations among ethnic groups, we sought to determine whether
the R263Q SNP also shows population-specific frequency
variations. In addition to the four SLE cohorts described
earlier, we also genotyped the SNP in African-American,
Caucasian, Asian, and Hispanic Control individuals and
observed that the frequency of Q263 carriers is 4% in
Caucasians and Hispanics, while carriers are even rarer
among African-Americans and Asians (Table 3). Thus,
the R263Q SNP does not appear to have significant allele
570 Human Molecular Genetics, 2009, Vol. 18, No. 3
frequency differences across ethnicities but it remains to be
determined whether larger variation occurs across different
European populations, analogous to what has been reported
for the R620W SNP (13). Lastly, when we compared the
sequences of the catalytic domains from all available LYP
homologs in the NCBI (National Center for Biotechnology
Information) database we observed that, with the exception
of humans, who contain an R at position 263, the amino
acid at the homologous site in all of the other species is invari-
ably a Q (Fig. 5), demonstrating that the ancestral enzyme
encodes Q at position 263. Because it has been hypothesized
that the PTPN22 locus is under positive selective pressure
Figure 1. LYP–Q263 is a loss-of-function variant of LYP. (A–D) Study of the inhibitory activity of LYP–R263 and –Q263 on TCR signaling at the single-cell
level. JTAg cells were transfected with LYP–R263 or –Q263 and left unstimulated or stimulated with C305 for 20. Cells were immediately fixed, permeabilized,
and co-stained with an Alexa Fluor488 (AF488)-conjugated anti-LYP antibody and a PE-conjugated anti-pSLP-76(Tyr128) antibody. Cells overexpressing LYP
were gated by comparing AF488 fluorescence histograms of transfected and untransfected cells. (A) Anti-HA western blots of total lysates of untransfected cells
(lane 1), and cells transfected with HA–LYP–R263 (lane 2) or HA–LYP–Q263 (lane 3). (B) Expression of LYP in transfected cells, detected by flow cytometry
after gating on LYP-overexpressing cells. (C) pSLP-76 levels in TCR-stimulated cells transfected with LYP–R263 (continuous black graph) or with LYP–Q263
(dotted black graph) and gated as described, or in untransfected cells (tiled gray graph). pSLP-76 levels in unstimulated transfected cells were almost undetect-
able. The difference between LYP–R263 and LYP–Q263 calculated by Overton subtraction is shown above the graph. Data in panel (A–C) are representative of
three experiments with similar results. (D) Activation of ERK2 is less inhibited in T-cells transfected with LYP–Q263. Myc-tagged ERK2 was co-transfected in
JTAg cells together with HA–LYP–R263 (lanes 1,2) or with HA–LYP–Q263 (lanes 3,4). Cells were left unstimulated (lanes 1,3) or were stimulated with C305
for 20 (lanes 2,4). (a) Shows an anti-pERK2 blot, (b) shows an anti-ERK2 blot of anti-myc immunoprecipitations, and (c) shows anti-LYP blot of total lysates.
Numbers below each lane indicate densitometry results. The figure shows one of two independent experiments with similar results. (E) Activation of an NFAT/
AP1 reporter in T-cells transfected with LYP–R263 or LYP–Q263. JTAg cells were co-transfected with a 3xNFAT/AP1 luciferase reporter and LYP–R263 or
LYP–Q263. Cells were stimulated for 7 h with OKT3, lysed and luciferase activity measured on cell lysates. The average+SD stimulation-induced increase in
the ratio between firefly and Renilla luciferase activities of lysates of cells transfected with LYP–R263 (filled squares, continuous line) or LYP–Q263 (open
squares, dotted line)—both measured in triplicate—was plotted versus LYP expression in the same lysates as assessed by anti-HA western blot. Lines are non-
linear fitting of data to a third-order polynomial. The figure shows one of two independent experiments with similar results.
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(14), it would be interesting to determine whether the R263
allele also rose to such a high frequency in humans as a
result of positive selection, since it can be considered a
‘gain-of-function’ allele relative to the ancestral Q263 variant.
DISCUSSION
Reduced TCR signaling has recently emerged as an important
causal factor in the development of autoimmunity. In this
regard, the R620W SNP in PTPN22, which reduces TCR sig-
naling as a result of increased phosphatase activity, predis-
poses to several autoimmune disorders. In contrast, we
demonstrate that a loss-of-function variant (R263Q), which
is less effective in reducing TCR signaling, protects against
SLE. The bi-directional association of PTPN22 with autoim-
munity has potentially important therapeutic implications
since it has been proposed that inhibition of LYP activity,
which would presumably enhance TCR signaling, could help
Figure 2. LYP–Q263 shows decreased phosphatase activity. (A) The Q263 allele shows lower phosphatase activity than R263. JTAg cells were transfected with
HA–LYP–R263 or HA–LYP–Q263 or an inactive (C227S) variant of HA–LYP–R263. HA–LYP was immunoprecipitated from cell lysates and its phosphatase
activity was assessed under Vmax conditions using DiFMUP as a substrate. Left panel shows anti-HA blot of an aliquot of immunoprecipitations (IPs) from cells
transfected with HA–LYP–R263 (lane 1), HA–LYP–Q263 (lane 2) or HA–LYP–C227S (lane 3). Histogram showing average+SD activity of immunopreci-
pitated HA–LYP–R263 (black column) or HA–LYP–Q263 (shaded column), normalized for LYP expression as assessed by anti-HA blots of fractions of
IPs taken before resuspension in the final phosphatase buffer, and corrected for the activity associated with HA–LYP–C227S immunoprecipitates. The statistical
significance of the difference between LYP–Q263 and LYP–R263 was calculated by Student’s t-test (P-value shown above the Q263 column). Figure shows one
representative experiment of three independent replicates with similar results. (B) Coomassie-stained polyacrylamide gel showing 300 ng of Cat-R263 (lane 1) or
Cat-Q263 (lane 2). (C–E) Activity of Cat-R263 (continuous graphs) and Cat-Q263 (dotted graphs) on three different substrates. Panels show activity on
14LckpY394, a 14 amino acid phospho-peptide ARLIEDNE(pY)TAREG, derived from the Tyr394 auto-phosphorylation site of Lck (C), or p-NPP (D), or
DiFMUP (E). The average+SD activity of Cat-R263 (filled squares) and Cat-Q263 (open squares) measured in triplicate was plotted versus substrate concentration,
and data were fitted to the Michaelis–Menten equation (for p-NPP and DiFMUP) or the Michaelis–Menten with substrate inhibition (for the 14LckpY394 peptide)
equations (continuous and dotted lines). Calculated catalytic parameters with 95% CI are reported below each graph.
Figure 3. Structural basis for the reduced activity of LYP–Q263. (A) Superimposed structures of Cat-Q263 (purple) on Cat-R263 (yellow) show an open WPD
loop and replacement of the LYP-specific loop with an extended helix in the mutant. The catalytic cysteine (C227) is shown in green. (B) The R263Q mutation in
the LYP catalytic domain eliminates the contacts of R263 a5 helix to the a20 helix on the main-chain carbonyl oxygen of Q34. (C) Movement of the WPD loop
to the open conformation in R263Q. (D,E) Surface electrostatics of the (D) Cat-R263 and (E) Cat-Q263 structures. The deep electropositive cleft stretches from
the active site to the LYP-specific loop, which is marked by gray sticks. When the LYP-specific region adopts the helical conformation in Cat-Q263 and shifts
away from residue 263, the cleft conformation changes, which may reduce the efficiency of substrate processing by the enzyme.
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prevent or treat such diseases (10). Stimulation of the TCR
through a different mechanism has been shown to have cura-
tive effects in mouse models of T1D and to benefit human
autoimmunity patients (15). In addition, the allele-specific
inhibitory effect of IC-11 on LYP activity has implications
for individualized therapeutic strategies (16). Our data
suggest that patients carrying the Q263 variant might not
benefit as much as non-carriers from inhibitors of LYP. More-
over, these experiments provide independent confirmation of
our structural derivation as well as the interaction model pro-
posed by Yu et al. for IC-11.
Considering that the PTPN22 R620W polymorphism pre-
disposes to several autoimmune diseases, it is likely that the
PTPN22 Q263 allele associates with multiple autoimmune dis-
eases as well. For example, recently Skinningsrud et al. (17)
reported a protective trend for the Q263 allele in Addison’s
disease. However, compared with the predisposition conferred
by the R620W variant, the protective effect of R263Q appears
to be weaker and, interestingly, it does not extend to T1D (12).
One explanation for this observation is that a loss-of-function
effect on TCR signaling is more easily compensated for than a
gain-of-function effect. In addition, the quantitative thresholds
between TCR signaling and the development of disease path-
ology are likely different in various autoimmune diseases. We
speculate that for example a larger reduction in signal trans-
duction through the TCR may be required for predisposition
to SLE than to T1D. Experimental evidence is required to
determine whether this model is indeed biologically plausible.
MATERIALS AND METHODS
Human subjects and genotyping
The Spanish, Argentinean and Italian SLE Cases and their
clinical characteristics have all been previously described
(18,19). The 457 European-derived SLE patients recruited in
CA, USA, were an extension of the previously reported 60
multiplex and 258 simplex SLE families (20) and 358
normal Controls of European descent were also ascertained
at the same site. In addition, 122 SLE patients and 209 Con-
trols of European ancestry were recruited in Houston, TX,
USA, as described (21). For the US cohort, self-reported
ethnic origin of the four grandparents of the SLE patient and
Controls (if known) were used to classify European ancestry.
All cases fulfill the 1982 American College of Rheumatology
criteria for the classification of SLE (22). All participating
subjects provided informed consent for the study. The study
was approved by the various Institutional Review Boards
and Ethnical Committees at each of the participating locations.
The genotyping for SNP rs33996649 was performed using a
Custom-Taqman-SNP-Genotyping-Assay (Applied Biosys-
tems, Foster City, CA, USA). The primer sequences were:
forward 50 TTTGAACTAATGAAGGCCTCTGTGT 30 and
reverse 50 ATTCCTGAGAACTTCAGTGTTTTCAGT 30.
The specific minor groove binder probe sequences were 50
TTGATCCGGGAAATG 30 and 50 TTGATCCAGGAAATG 30.
Plasmids, antibodies and reagents
Full-length LYP was cloned in the BamHI site of the plasmid
pEF5 (23), which allows the expression of constructs in fusion
with an N-terminal HA tag, and under control of the EF1alpha
(elongation factor 1 alpha) promoter. Mutagenesis was per-
formed by site-directed mutation primers, using Pfu-Ultra
polymerase (Stratagene, San Diego, CA, USA) for PCR (poly-
merase chain reaction) amplification; all mutants were
assessed by full-length sequencing. The anti-LYP antibody
Table 1. Data collection and refinement statistics for Cat structure
Crystal cell parameters
Space group P1
Cell dimensions
(a, b, c in A˚) 41.597, 57.934, 67.869
(a, b, g in 8) 90.069, 90.041, 105.689
Data collection statistics
Resolution range (A˚) 50.0–2.65
Observations 42 970
Unique reflections 16 878
Completeness (%) 95.1 (86.3)
Rsym (%) (last bin) 8.6 (26.0)
I/s (last bin) 16.1 (4.0)
Refinement statistics
Resolution range (A˚) 40.0–2.65
Rcryst (%) 21.6
Rfree (%) 27.8
RMS deviation
Bond length (A˚) 0.009
Bond angle (8) 1.9
Average B factor (A˚2) 44.3
Note: Rsym ¼
P
ij jIi(j)2 ,I(j).j/
P
ij Ii(j), where Ii(j) is the i-th
measurement of reflection j and ,I(j). is the overall weighted mean of i
measurements. Rcryst ¼ ShklkFoj-jFck/ShkljFoj, 7% of the reflections
were excluded for the Rfree calculation.
Figure 4. R263Q polymorphism affects inhibition of LYP by a small molecule
inhibitor which interacts with the LYP-specific loop. Graph shows dose–
response inhibition of Cat-R263 (filled squares and continuous line) or
Cat-Q263 (open squares and dotted line) by IC-11, using the 14LckpY394
peptide as substrate. The reaction was carried out for 4 min using equal
units of enzyme, and 30 mM substrate (this concentration is within the 95%
CI of the KM of both enzymes) in phosphatase buffer. The average+SD
activity of Cat-R263 (filled squares) and Cat-Q263 (open squares) measured
in triplicate was plotted versus inhibitor concentration. The data were fitted
to a Boltzmann sigmoidal, in order to calculate IC-50 (continuous and
dotted lines). The statistical significance of the difference between Cat-Q263
and Cat-R263 was calculated by two-tailed paired Student’s t-test (P-value
shown above the graph). The figure shows one of two independent exper-
iments with similar results.
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was purchased from R&D (Minneapolis, MN, USA). The
monoclonal anti-HA antibody (clone 16B12) was purchased
from Covance (Berkeley, CA, USA). The anti-ERK2 (C14)
antibody and the monoclonal anti-Myc antibody (clone
9E10) were purchased from Santa Cruz Biotech (Santa Cruz,
CA, USA). The PE(phycoerythrin)-conjugated anti-pSLP-76
(Tyr128) was purchased from BD Biosciences Pharmingen
(San Jose, CA, USA). The anti-ACTIVE MAPK (anti-pERK)
was from Promega (Madison, WI, USA).
Cell culture, transfections, cell stimulation
Jurkat T leukemia cells expressing SV-40 large T Antigen
(JTAg) (24) were kept at logarithmic growth in Roswell
Park Memorial Institute (RPMI) 1640 medium supplemented
with 10% fetal calf serum, 2 mM L-glutamine, 1 mM sodium
pyruvate, 10 mM HEPES pH 7.3, 2.5 mg/ml D-glucose, 100
units/ml of penicillin and 100 mg/ml streptomycin. Transfec-
tions were performed by electroporation as described (7).
Short-term stimulation of JTAg cells was achieved by using
C305 hybridoma (25) supernatants.
Phospho-flow cytometry
The anti-LYP antibody was conjugated with AF488 using a
commercial conjugation kit (Pierce, Rockford, IL, USA) and
the AF488-conjugated antibody was optimized for detection
of LYP expression in flow cytometry (data not shown).
Phospho-flow cytometry was performed on transfected JTAg
cells following the manufacturer’s instructions (BD Bio-
sciences Pharmingen). Cells were fixed with BD Cytofix
buffer, permeabilized using BD Phosflow buffer III and
stained with AF488-conjugated anti-LYP and PE-conjugated
anti-pSLP-76 (Tyr128) antibodies. Cell fluorescence was
assessed on a Cytomics FC500 cytometer (Beckman Coulter,
Fullerton, CA, USA) at the USC Immune Monitoring Core.
Flow cytometry data analysis and graph preparation were
carried out using FlowJo (Tree Star, Inc., Ashland, OR,
USA). Differences between distributions were calculated
by Overton subtraction (26). The sampling error in
C305-stimulated JTAg cells was evaluated by measuring the
average+SD Overton subtraction% of three independent
replicates and was 2.5+ 0.6% for the anti-pSLP-76 antibody.
Immunoprecipitations and western blot analysis
For immunoprecipitations (IPs), cells were lysed in 20 mM
Tris–HCl pH 7.4, 150 mM NaCl, and 1 mM EDTA (TNE
buffer), with 1 mM phenylmethanesulphonylfluoride, 10 mg/mlT
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Table 3. Frequency of PTPN22 G788A (R263Q) genotypes in five ethnic
groups
Population n GG R263/
R263
GA R263/
Q263
AA Q263/
Q263
GA%
Caucasian 241 231 10 0 4.15
Hispanic 132 125 7 0 5.30
African-American 69 67 1 0 1.45
Asian 28 28 0 0 0.00
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Figure 5. Q263 allele defines the ancestral LYP variant. Alignment of catalytic domains of LYP from Homo sapiens (gi:48928054), Pan troglotides
(gi:114558717), Macaca mulatta (gi:109014421), Mus musculus (gi:6679555), Rattus Norvegicus (gi:157824150), Bos taurus (gi:119889627) and Gallus
gallus (gi:118102481). The residue in position 263 is highlighted in gray.
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aprotinin/leupeptin, 10 mg/ml soybean trypsin inhibitor, and
10 mM sodium orthovanadate. Anti-HA antibody was added
to the lysates, followed by sepharose-conjugated Protein G
Sepharose (GE healthcare, Piscataway, NJ, USA) to precipi-
tate the antibody–antigen complex. The beads were washed
four to five times in lysis buffer, and resuspended in SDS
sample buffer. Proteins were run on denaturing SDS–poly-
acrylamide gels (Invitrogen, Carlsbad, CA, USA), and
transferred to nitrocellulose filters (Hybond ECL, GE
Healthcare). Western blots were performed using appropriate
dilutions of unconjugated primary antibodies, followed by
HRP(horseradish peroxidase)-conjugated secondary anti-
bodies (purchased from GE Healthcare). Filters were then
subjected to a chemiluminescent detection protocol using
ECL Plus (GE Healthcare) followed by autoradiography
(using films from Kodak, Rochester, NY, USA).
Luciferase assays
Luciferase assays were performed as previously described (7).
The NFAT/AP1 reporter plasmid (kindly provided by Dr
Gerald Crabtree, Stanford University, Stanford, CA, USA)
carries three tandem copies of the distal NFAT/AP1 composite
element of the human IL2 promoter (24) which are cloned
upstream of the minimal IL2 promoter (from 289 to þ51)
and the luciferase reporter gene. The NFAT/AP1 reporter
plasmid and the Control pGL3 plasmid, driving constitutive
expression of Renilla luciferase, were co-transfected in JTAg
cells with variable amounts of the appropriate HA–LYP
constructs. Cells were subjected to TCR stimulation with
anti-CD3 [OKT3, purified from hybridoma supernatants
(27)] for 7 h. Luciferase assays were then performed in tripli-
cate on cell lysates using the dual luciferase kit from Promega
according to the manufacturer’s instructions, and lumines-
cence measured on a Perkin Elmer 1420 Multilabel Counter
Victor III V plate reader (Perkin-Elmer, Turku, Finland).
The difference in the ratio between firefly and Renilla
luciferase activity in stimulated versus unstimulated cells
(TCR-induced increased activation of reporter) was then
plotted against the expression of LYP assessed by densito-
metric scanning of anti-HA blots of total lysates.
Purification of recombinant proteins
The catalytic domain (amino acid 2–309) of LYP–R263 or
LYP–Q263 (Cat-R263 and Cat-Q263) were cloned between
the BamHI and the XhoI sites of the pET28a vector (EMD
Chemicals, Gibbstown, NJ, USA) and expressed in BL21
Escherichia coli cells in fusion with a thrombin-cleavable
N-terminal 6xHis tag. Recombinant Cat was isolated from
lysates of IPTG(isopropyl b-D-1-thiogalactopyranoside)-
induced bacteria by two steps of affinity chromatography.
Bacterial lysates were loaded on a Ni2þ-NTA column
(Qiagen, Inc., Valencia, CA, USA) and the untagged protein
was eluted by incubating the column with thrombin, followed
by removal of thrombin through a second step on a
benzamidin-sepharose column. As shown in Fig. 2B, the
purified proteins were evident as single 37 kDa bands on
denaturing SDS–polyacrylamide gels and their purity was at
least 99% by Coomassie staining. Protein concentration was
quantified by assessing absorbance of protein solutions at
280 nm, and confirmed by comparison with BSA standards
on Coomassie-stained SDS–denaturing gels.
Phosphatase assays
In order to detect the phosphatase activity of full-length LYP
immunoprecipitated from transfected JTAg cells, immunopre-
cipitates were washed three times in 100 mM Bis–Tris pH 6.0,
and resuspended in phosphatase buffer (50–100 mM Bis–Tris,
pH 6.0, 1–5 mM DTT). IPs were incubated with 0.5 mM
6,8-di-fluoro-4-methylumbelliferyl phosphate (DiFMUP), and
dephosphorylation of DiFMUP was monitored continuously
by measuring the increase in fluorescence (lexc¼ 355 nm
and lem¼ 460 nm) at 60 s intervals for 30 min. The LYP-
attributable activity of IPs measured in triplicate was
calculated by subtracting the aspecific activity (also measured
in triplicate) of identical IPs performed from lysates of cells
transfected with inactive LYP–S227. The LYP-attributable
activity was subsequently normalized for LYP expression as
assessed by anti-HA blots of fractions of IPs taken before
resuspension in the final phosphatase buffer. The activity of
Cat was detected in the phosphatase buffer using para-
nitrophenylphosphate (p-NPP), or DiFMUP, or a 14 amino
acid pTyr peptide ARLIEDNE(pY)TAREG, derived from
the Lck-Tyr394 phosphorylation site (14LckpY394). Depho-
sphorylation of DiFMUP was detected as described earlier.
When the pTyr-peptide was used as substrate, the reaction
was stopped by addition of BIOMOL GREENTM (Biomol
International, LP, Plymouth Meeting, PA, USA) and the phos-
phate released was detected by measuring the absorbance at
595 nm. When p-NPP was used as substrate, the reaction
was stopped by addition of 1.0 M NaOH, and the activity
was detected by monitoring the absorbance of para-
nitrophenol at 405 nm. Fluorescence and absorbance were
measured using the previously mentioned plate reader. The
phosphatase activity measured in triplicate was corrected for
the aspecific signal of identical reactions performed also in
triplicate without addition of enzyme. Data were fit to the
Michaelis–Menten equation or to the Michaelis–Menten
with substrate inhibition equation (28), and kinetic parameters
were calculated for each substrate. Amount of enzymes and
time of incubation in all phosphatase assays were optimized
in order to ensure initial rate conditions.
Protein crystallization and structure solution
Crystallization and data collection. Crystals of the Cat-Q263
variant were obtained using the vapor diffusion method at
188C using a precipitant containing 2.0 M ammonium sulfate,
1% ethanol, 0.2 M sodium-potassium phosphate in 0.1 M
MES, pH 6.2 in the buffer and pH 5.8 in the drop. Crystals
appeared within 3–5 days and grew to full size in 1.5
weeks. Plate-shaped crystals were flash frozen after a quick
soaking in a cryo solution containing 15% glycerol, 2.0 M
ammonium sulfate, 0.2 M sodium–potassium phosphate in
0.1 M MES (pH 6.2) and diffraction data up to 2.65 A˚ were
collected at in-house R-AXIS IVþþ image plate. The data
were processed using HKL2000, and data statistics are
shown in Table 1.
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Structure determination and refinement. The structure of the
Cat-Q263 variant was solved by molecular replacement
method (MOLREP) using the coordinates of wild-type Cat
as the search model. The residue at mutation site and some
of its neighbors were mutated to Ala in the search model.
The N-terminal a10 and a20 helices and several other loops
were deleted to avoid model bias. The model was refined
using alternate cycles of refinement in crystallography &
NMR system (CNS) and model building in ‘O’. The mutated
residue, truncated helices, loops and the side chains were
gradually added to the model, guided by the electron density
map, and the model was refined further using the standard
slow-cool and positional refinement protocols of CNS
package using the data between 40 and 2.65 A˚. The model
was finally checked in a composite omit electron density
map. Progressive inclusion of water molecules, the bound
phosphate ion, and MES coupled with a few cycles of refine-
ment yielded an Rcryst of 21.6% (Rfree ¼ 27.8%). Refinement
statistics are given in Table 1.
Statistical analysis, graphs and experimental
error calculations
Allelic and genotypic frequencies were calculated and com-
pared by x2 tests using the Statcalc software (Epi Info 2002;
Centers for Disease Control and Prevention, Atlanta, GA,
USA) or the Stata software version 8 (Stata Corp., College
Station, TX, USA). Significance was calculated by 2  2 con-
tingency table and Fisher’s exact test, to obtain P-values, OR
and 95% CI. Statistical significance was considered when P ,
0.05. The Breslow–Day test was used to test for homogeneity
of the stratum specific ORs. This test did not indicate signifi-
cant departure from homogeneity (P ¼ 0.78), thus we com-
puted the Mantel–Haenszel test for an overall association
between R263Q variant and SLE, after controlling for popu-
lation. The Haploview software was used to obtain LD pair-
wise values. As an overall test for association of R263Q
SNP independent of R620W, we performed a conditional
Case–Control test implemented in the UNPHASED software
(http://portal.litbio.org/Registered/Webapp/glue/). Graphs,
curve fitting, and kinetic parameter calculations were per-
formed using the Graphpad Prism software package (Graph-
pad, San Diego, CA, USA). Sequence alignment was
performed using ClustalW (29). All SD of differences and
ratios were calculated according to the error propagation
rules described by Taylor (30).
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